These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35955767)

  • 21. The risk factors for complications and survival outcomes of Klebsiella pneumoniae Bacteraemia in Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia.
    Ang SH; Petrick P; Shamsul AS; Ramliza R; Kori N; Lau CL
    Med J Malaysia; 2022 Jul; 77(4):440-445. PubMed ID: 35902933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H
    Toliver-Kinsky T; Cui W; Törö G; Lee SJ; Shatalin K; Nudler E; Szabo C
    Infect Immun; 2019 Jan; 87(1):. PubMed ID: 30323021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of two H2S-producing, multiple drug-resistant isolates of Escherichia coli from clinical urine specimens.
    Traub WH; Kleber I
    Pathol Microbiol (Basel); 1975; 43(1):10-6. PubMed ID: 775411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.
    Matsumura Y; Yamamoto M; Matsushima A; Nagao M; Ito Y; Takakura S; Ichiyama S
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1931-9. PubMed ID: 22210267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
    Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
    Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
    Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
    [No Abstract]   [Full Text] [Related]  

  • 29. Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital.
    Lee S; Han SW; Kim KW; Song DY; Kwon KT
    Korean J Intern Med; 2014 Jan; 29(1):49-56. PubMed ID: 24574833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes.
    Marschall J; Agniel D; Fraser VJ; Doherty J; Warren DK
    J Antimicrob Chemother; 2008 Jun; 61(6):1376-83. PubMed ID: 18344548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of hydrogen sulfide from sulfur assimilation in Escherichia coli.
    Tanaka N; Hatano T; Saito S; Wakabayashi Y; Abe T; Kawano Y; Ohtsu I
    J Gen Appl Microbiol; 2019 Dec; 65(5):234-239. PubMed ID: 30880290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of patients with bacteraemia due to the emergence of mcr-1-harbouring Enterobacteriaceae in humans and pigs in Taiwan.
    Lai CC; Lin YT; Lin YT; Lu MC; Shi ZY; Chen YS; Wang LS; Tseng SH; Lin CN; Chen YH; Ko WC; Wang FD; Hsueh PR;
    Int J Antimicrob Agents; 2018 Nov; 52(5):651-657. PubMed ID: 30145246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nrf2 Activation Protects Against Organic Dust and Hydrogen Sulfide Exposure Induced Epithelial Barrier Loss and
    Shrestha D; Massey N; Bhat SM; Jelesijević T; Sahin O; Zhang Q; Bailey KL; Poole JA; Charavaryamath C
    Front Cell Infect Microbiol; 2022; 12():848773. PubMed ID: 35521223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
    BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antimicrobial resistances and clinical features in community-onset Escherichia coli and Klebsiella pneumoniae bacteremia.
    Sung HS; Lee JW; Bae S; Kwon KT
    Korean J Intern Med; 2021 Mar; 36(2):433-440. PubMed ID: 32229796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year longitudinal molecular epidemiology study of Escherichia coli and Klebsiella species bloodstream infections in Oxfordshire, UK.
    Lipworth S; Vihta KD; Chau K; Barker L; George S; Kavanagh J; Davies T; Vaughan A; Andersson M; Jeffery K; Oakley S; Morgan M; Hopkins S; Peto TEA; Crook DW; Walker AS; Stoesser N
    Genome Med; 2021 Sep; 13(1):144. PubMed ID: 34479643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.